Subscribe
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma
Articles
Articles
FDA Expedites Approval of Pertuzumab for Metastatic HER2 Breast Cancer
FDA Approvals, News & Updates
June 2012, Vol 3, No 4
The US Food and Drug Administration (FDA) approved pertuzumab (Perjeta; Genentech) for intravenous use in patients with HER2-positive metastatic breast cancer.
Read More
Can Pathways Improve Quality of Care While Reducing Cost?
By
Neil Canavan
ACCC Annual Meeting
June 2012, Vol 3, No 4
Baltimore, MD—Changes are constant in cancer care—new technologies, new targets, and new treatments. But the associated spiraling costs are also constant.
Read More
Regional Cancer Care Associates: Consolidating Small Practices into a Large Consortium
Best Practices
,
Policies & Guidelines
June 2012, Vol 3, No 4
Value-Based Cancer Care
is focused on examining value within the context of healthcare stakeholder relations. Dr Pecora and his team at Regional Cancer Care Associates (RCCA) have changed the relationship between the practicing oncologist and the payer, which will have substantial effects on value.
Read More
“Precision Medicine” the Theme of ASCO 2012
By
Caroline Helwick
ASCO Annual Meeting
,
ASCO
June 2012, Vol 3, No 4
Chicago, IL—“Precision medicine” is the new catch phrase in oncology, and examples of it were evident across the vast halls of McCormick Place at the 2012 American Society of Clinical Oncology (ASCO) meeting.
Read More
Pathways in Oncology: Implications for Providers, Payers, and Patients
June 2012, Vol 3, No 4
Houston, TX—At the Second Annual Association for Value-Based Cancer Care Conference on March 29-31, 2012, a panel of payers and providers considered the role of pathways in oncology practice and the potential implications for end-of-life concerns.
Read More
Biomarker Identifies Patients with Rare Brain Tumors Who Have a Survival Benefit from Chemotherapy Plus Radiation
By
Phoebe Starr
ASCO Annual Meeting
,
ASCO
June 2012, Vol 3, No 4
Patients with the relatively rare brain tumor anaplastic oligodendroglioma who were treated with adjuvant chemotherapy after standard radiation therapy had improved survival compared with radiation alone, especially if they had codeletion of chromosomes 1p/19q, according to long-term follow-up of the EORTC (European Organisation for Research and Treatment of Cancer) 2651 study reported at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Read More
Evolving Practice Standards for Cancer Programs from the Commission on Cancer
By
M. Asa Carter, CTR
Cancer Care
,
Personalized Medicine
May 2012, Vol 3, No 3
What is the most important challenge faced by a person who is diagnosed with cancer today? Opinions will differ, but most patients want to be assured that they will work with a group of multispecialty physicians who will provide recommendations for care that provide the best possible outcomes, that all options for effective treatment will be available to them, that care will be provided in a safe and comfortable hospital or other facility, and that the healthcare staff will care about their problems and concerns with managing treatment, professional issues, and family issues.
Read More
Can Whole-Genome Sequencing Predict Future Cancer?
AACR Annual Meeting
May 2012, Vol 3, No 3
Chicago, IL—For the individual at average risk for disease, whole-genome sequencing (WGS)—mapping the sequence of one’s full set of genetic material—is not a crystal ball to reliably predict future health, according to a study presented at the 2012 American Association for Cancer Research meeting.
Read More
Metformin Protects Against Several Cancers
By
Richard Hyer
AACR Annual Meeting
May 2012, Vol 3, No 3
Chicago, IL—Metformin cannot seem to stay out of the news. This antidiabetes drug that is derived from the French lilac is now also thought to possibly protect against liver cancer, lower the risk for oral cancer, improve prognosis of pancreatic cancer in diabetic patients, and increase response to melanoma tumors with BRAF mutations when used in combination with a common cancer drug, according to several studies presented at the 2012 American Association for Cancer Research meeting.
Read More
Advances in Personalized Medicine: Focus on Prostate and Brain Cancers
By
Richard Hyer
AACR Annual Meeting
May 2012, Vol 3, No 3
Chicago, IL—Targeting prostate cancer with extreme accuracy, using tissue oxygen content to predict its recurrence, and using breast cancer drugs on brain tumors were a few highlights of a news conference on advances in personalized medicine at the 2012 American Association for Cancer Research meeting.
Read More
Page 289 of 329
286
287
288
289
290
291
292
Top Trending Articles
1.
ACCC Federal Policy Update Highlights Key Risks and Opportunities for Oncology Practices in 2026
Meg Barbor, MPH
2.
From Chaos to Clarity: Data-Driven Denial Prevention
Shawntea (Taya) Gordon, MBA, FACMPE
3.
The Evolving Landscape of Lung Cancer Care
Meg Barbor, MPH
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma